Latest Feature

Kimberly-Clark readies Halyard Health medical device spinout

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

HART CEO David Green on the transformative potential for regenerative medicine

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Diabetes: FDA OKs 1st glucose meter with insulin calculator

September 18, 2014 by Arezu Sarvestani

Roche lands FDA clearance for its Accu-Chek Aviva Expert, the 1st diabetes management device to combine a blood glucose meter with an insulin calculator.

Diabetes: FDA OKs 1st glucose meter with insulin calculator

Biotech titan Roche secured a landmark FDA win with clearance for its Accu-Chek Aviva Expert blood glucose meter, the 1st of its kind with a built-in insulin calculator to help guide patient therapy.

Press Release: ACCU-CHEK Aviva Expert, the first and only stand-alone blood glucose meter system with a built-in insulin calculator, is now available

September 18, 2014 by MassDevice

ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.

Press Release: ACCU-CHEK Aviva Expert, the first and only stand-alone blood glucose meter system with a built-in insulin calculator, is now available

Healthcare sneakers test cybersecurity in medtech | MassDevice.com On Call

September 18, 2014 by Arezu Sarvestani

As the healthcare industry suffers a growing number of digital attacks and hacks, cybersecurity experts offer tips for penetration testing and "how to hack your own medical device."

MassDevice.com On Call

MASSDEVICE ON CALL — Digital criminals have been stepping up their game with an ever-increasing number of malicious hacks on healthcare data systems, but there is good news. The medical device industry doesn't have to reinvent the wheel to get a grasp on its cybersecurity issues.

Other industries have been in the cybersecurity limelight for years and there are several defined practices to help companies assess and improve their digital defenses.

Intrinsic Therapeutics raises $17.2M for spinal surgery devices

September 18, 2014 by Arezu Sarvestani

Intrinsic Therapeutics needs about $3.6 million to close a $20.9 million funding round in supports of its spinal devices.

Intrinsic Therapeutics raises $17.2M for spinal surgery devices

Massachusetts-based Intrinsic Therapeutics is nearing the close of a $20.9 million equity round, with about $17.3 million raised so far.

MassDevice.com +3 | The top 3 medtech stories for September 17, 2014

September 17, 2014 by MassDevice

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

 

Inside the Medtronic-Covidien deal: Contrasting styles brought the companies together

September 17, 2014 by Brian Johnson

A senior executive at Medtronic, vice president of corporate development Chris Cleary, explains how Covidien played "scrappy" upstart all the way to a $43 billion payout.

Inside the Medtronic-Covidien deal: Contrasting styles brought the companies together

Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup

September 17, 2014 by Arezu Sarvestani

Abiomed unveils new results from an IDE study of its Impella Right Percutaneous heart pump, reporting 73% survival in patients with right ventricular failure.

TCT 2014 Roundup

Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.

Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp